Enhertu is a promising new treatment for patients with HER2-positive breast cancer.
Its advanced effects, including a higher response rate, effectiveness in treating patients with brain metastases, and a manageable safety profile, make it an important addition to the treatment options available for these patients.
Rated 5.00 out of 5
$2,627.25 – $3,295.25
Ibrance is a revolutionary medication that has transformed the treatment options for advanced breast cancer.
Its unique mechanism of action and high efficacy have made it a popular choice among oncologists and patients alike.
$3,444.22 – $5,519.54
Kadcyla is an advanced treatment option for HER2-positive breast cancer that offers improved outcomes and fewer side effects compared to traditional chemotherapy.
By targeting cancer cells specifically, this medication offers a more effective and precise approach to treating cancer and helping patients achieve a better quality of life.
Keytruda (pembrolizumab) is a powerful targeted therapy that has shown great promise in treating advanced and metastatic cancers.
Its ability to block the PD-1 pathway and stimulate the immune system’s response to cancer cells makes it a valuable tool in the fight against many types of cancer,
Rated 5.00 out of 5
Kisqali is a prescription medication that is used in the treatment of patients with HR+ breast cancer.
The drug is taken in combination with an AI or fulvestrant and works by inhibiting the activity of CDK4/6 proteins, which are essential in the growth and division of cancer cells.
Rated 5.00 out of 5
Lynparza is a cutting-edge therapy that is expected to transform the cancer treatment space and change the lives of patients diagnosed with various forms of cancer.
Lynparza precision and specificity guarantee that it targets only cancer cells while minimizing damage to healthy cells.
Margenza is a promising new treatment option for patients with HER2-positive breast cancer, offering a significant improvement in clinical outcomes for patients with advanced HER2-positive breast cancer, who have already been treated with trastuzumab and pertuzumab therapy.
The extended half-life of the drug and its potency offer better outcomes for patients, and the reduced frequency of dosing makes the treatment significantly more convenient for patients.
Nerlynx is an advanced medication that offers new hope for patients with HER2-positive breast cancer who have completed trastuzumab-based therapy.
Its ability to significantly reduce the risk of recurrence and delay the onset of brain metastases makes it a valuable treatment option for patients. 240 mg (6 tablets) taken once daily with food
Perjeta is an advanced and highly effective medication for the treatment of HER2-positive breast cancer.
The drug has been shown to have a significant impact on the progression of cancer, and is a key component of many breast cancer treatment plans.
$7,700.00 – $10,500.00
Piqray is an advanced medication that holds significant potential for improving the prognosis of patients with advanced breast cancer.
Its ability to target the PI3K enzyme has shown great promise in preventing cancer growth and spreading to other parts of the body
Tecentriq (Atezolizumab) represents a significant advancement in the treatment of cancer and other diseases.
Its ability to enhance the immune response and modulate the immune system has enormous potential in a wide range of conditions beyond cancer.
Trodelvy (sacituzumab govitecan-hziy) is a breakthrough medication that offers hope for patients with metastatic TNBC who have limited treatment options.
The medication is highly effective, with clinically proven response rates, better overall survival, and a well-tolerated safety profile.
$3,224.92 – $18,180.00
Tukysa represents an important new option for the treatment of advanced HER2-positive breast cancer.
By targeting the HER2 protein, Tukysa can help to slow the growth and spread of cancer cells, improving patient outcomes and extending survival.